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CLINICAL SCIENCE
Laboratory-Reflex Cryptococcal Antigen Screening Is
Associated With a Survival Benefit in Tanzania
Diana Faini, MD,*† Aneth Vedastus Kalinjuma, BSc,* Andrew Katende, MD,* Gladys Mbwaji, MD,*
Dorcas Mnzava, BSc,* Amina Nyuri, BSc,* Tracy R. Glass, PhD,‡§ Hansjakob Furrer, MD,║
Christoph Hatz, MD,‡§ David R. Boulware, MD, MPH,¶ and Emilio Letang, MD, MPH, PhD,*‡§#**
on behalf of the KIULARCO Study Group
Background: Cryptococcal antigen (CrAg) screening in persons
with advanced HIV/AIDS is recommended to prevent death.
Implementing CrAg screening only in outpatients may underestimate
the true CrAg prevalence and decrease its potential impact. Our
previous 12-month survival/retention in CrAg-positive persons not
treated with ﬂuconazole was 0%.
Methods: HIV testing was offered to all antiretroviral therapy–
naive outpatients and hospitalized patients in Ifakara, Tanzania,
followed by laboratory-reﬂex CrAg screening for CD4 ,150 cells/
mL. CrAg-positive individuals were offered lumbar punctures, and
antifungals were tailored to the presence/absence of meningitis. We
assessed the impact on survival and retention-in-care using multi-
variate Cox-regression models.
Results: We screened 560 individuals for CrAg. The median CD4
count was 61 cells/mL (interquartile range 26–103). CrAg prevalence
was 6.1% (34/560) among individuals with CD4 #150 and 7.5%
among #100 cells/mL. CrAg prevalence was 2.3-fold higher among
hospitalized participants than in outpatients (12% vs 5.3%, P = 0.02).
We performed lumbar punctures in 94% (32/34), and 31% (10/34) had
cryptococcal meningitis. Mortality did not differ signiﬁcantly between
treated CrAg-positive without meningitis and CrAg-negative individuals
(7.3 vs 5.4 deaths per 100 person-years, respectively, P = 0.25).
Independent predictors of 6-month death/lost to follow-up were low
CD4, cryptococcal meningitis (adjusted hazard ratio 2.76, 95%
conﬁdence interval: 1.31 to 5.82), and no antiretroviral therapy initiation
(adjusted hazard ratio 3.12, 95% conﬁdence interval: 2.16 to 4.50).
Conclusions: Implementing laboratory-reﬂex CrAg screening among
outpatients and hospitalized individuals resulted in a rapid detection of
cryptococcosis and a survival beneﬁt. These results provide a model of
a feasible, effective, and scalable CrAg screening and treatment strategy
integrated into routine care in sub-Saharan Africa.
Key Words: cryptococcal meningitis, cryptococcal antigenemia,
HIV, ﬂuconazole, mortality, sub-Saharan Africa
(J Acquir Immune Deﬁc Syndr 2019;80:205–213)
INTRODUCTION
Cryptococcal meningitis accounts for ;15% of AIDS-
associated deaths, being a leading cause of mortality among
people living with HIV (PLHIV) recently enrolled into care and
initiating antiretroviral therapy (ART) in sub-Saharan Africa.1–4
To reduce this unacceptable high mortality in resource-limited
settings, the World Health Organization (WHO) recommends
early detection of subclinical cryptococcal antigen (CrAg) and
pre-emptive treatment of CrAg-positive individuals without
meningitis with ﬂuconazole.5–9
CrAg is detectable in plasma weeks to months before
onset of clinical symptoms, thus allowing for effective inter-
ventions to prevent the development of meningitis and decrease
mortality.10,11 In Tanzania, plasma CrAg prevalence has been
reported to range from 3% to 8% in different populations of
PLHIV,4,12–16 being consistent with that in other sub-Saharan
African countries.10
However, even with the early roll-out of ART and
implementation of the WHO guidelines, prospective data
still report high mortality among CrAg-positive individu-
als.3,4,17,18 There are several potential reasons for this,
including the increasing lack of available antifungal therapy,
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the implementation of these guidelines mostly among PLHIV
presenting at outpatient HIV clinics, and the low uptake of
diagnostic lumbar punctures (LPs) for asymptomatic CrAg-
positive individuals. Thus, this strategy may miss newly
diagnosed hospitalized PLHIV who have been documented
to have lower CD4 and therefore are at a higher risk of
cryptococcosis19–21 as well as paucisymptomatic early men-
ingitis cases. This may result in suboptimal antifungal
treatment for those individuals with subclinical cryptococcal
infection, putting them at risk of immune reconstitution
inﬂammatory syndrome and death after early ART initiation.4
A retrospective study conducted in 2008–2012 at our
facility, in Tanzania, reported a 4.4% CrAg prevalence among
ART-naive adult outpatients with CD4 ,100 cells/mL. We
observed 75% mortality/loss to follow-up (LFU) in CrAg-
positive individuals,16 similar as in Uganda.22 In this study,
the 12-month survival/retention in CrAg-positive persons
not treated with ﬂuconazole was 0%. Fluconazole receipt for
any reason decreased death or LFU among CrAg-positive
individuals.16
In October 2013, routine laboratory-reﬂex CrAg screen-
ing, routine LPs among CrAg-positive, and antifungal treat-
ment tailored to the presence or absence of meningitis were
implemented systematically at our institution among both
hospitalized patients and outpatients. We hypothesized that
the integration of this intervention into routine HIV care at our
rural facility will lead to improved survival of individuals
with cryptococcosis.
METHODS
Study Setting
This prospective study was nested in the Kilombero and
Ulanga Antiretroviral Cohort (KIULARCO) among adults
enrolled between October 2013 and July 2015. KIULARCO
is an ongoing, open, prospective cohort of PLHIV, estab-
lished in 2005. The KIULARCO cohort comprises individ-
uals visiting the Chronic Diseases Clinic of Ifakara (CDCI) at
the Saint Francis Referral Hospital (SFRH) giving written
informed consent to join the cohort. The SFRH is the largest
health care facility in the Kilombero district of the Morogoro
region in southern Tanzania, providing treatment and care for
a population of approximately 700,000 inhabitants and an
estimated 40,000 PLHIV. The CDCI is the ﬁrst rural clinic
accredited to be a care and treatment center for PLHIV in
Tanzania, with .9000 patients enrolled. Further KIULARCO
cohort details are published elsewhere.23,24
Since late 2013, provider-initiated HIV testing and
counseling (PITC) was universally implemented in the medical
wards of SFRH. In addition, we introduced an enhanced
package of care to improve cryptococcosis outcomes, including
(1) increased cryptococcal education and awareness; (2) bedside
ﬁnger-stick and laboratory-based plasma CrAg lateral ﬂow
assay (LFA; IMMY Inc, Norman, OK) reﬂex testing for
individuals with CD4 counts ,150 cells/mL; (3) routine
diagnostic LP for all plasma CrAg-positive individuals; (4)
serial therapeutic LPs for cryptococcal meningitis25; and (5)
optimized, standardized cryptococcosis treatment.
Study Design
This was a prospective longitudinal study of newly
diagnosed PLHIV, ART-naive adults 18 years and older, with
CD4 ,150 cells/mL, consented and enrolled in KIULARCO
from October 2013 to July 2015.
The exposure of interest was the CrAg status at baseline
screening, and the main outcome was mortality or LFU at 6
months after CrAg testing. The time of the event was deﬁned
as the date of death or last day of follow-up for participants
with .60 days passed since last visit. Participants who were
still retained-in-care after 6 months of follow-up from
baseline were right hand–censored at 6 months.
Laboratory-Based Plasma CrAg Lateral Flow Assay
After HIV diagnosis, all hospitalized patients and
outpatients with CD4 ,150 cells/mL underwent reﬂex
laboratory-based CrAg testing. CrAg LFA was performed
in our laboratory according to the manufacturer’s instruc-
tions from 40-mL plasma sample leftover drawn for CD4
count. Fingerstick CrAg LFA was also performed on
unconscious hospitalized PLHIV by pricking a sterilized
pad of the ﬁnger to produce 1 drop of whole blood placed
directly onto the LFA test strip. The test strips were then
placed in a 1.5-mL Eppendorf tube containing 2 drops of
sample diluent and left in an upright position at room
temperature for 10 minutes before reading.
All CrAg-positive results were communicated by phone
to the clinician in charge for immediate action. Semiquanti-
tative CrAg LFA titers were measured using 2-fold dilutions.
Clinical Evaluation
During clinical visits, vital signs and laboratory results
were reviewed, and a structured physical examination was
performed. Working diagnoses were captured through the
10th revision of the International Classiﬁcation of Diseases
and Health-Related problems (ICD-10) codes.26 Treatment
adherence, failure and toxicity, immune reconstitution inﬂam-
matory syndrome, and other clinical details were assessed,
recorded, and captured in the electronic databases of the
cohort.23,24 Tuberculosis screening was performed in all
individuals at baseline and during follow-up visits. Tubercu-
losis case diagnosis was deﬁned by either (1) positive
microbiologic tests (eg, Xpert MTB/RIF or microscopy with
acid-fast bacilli in sputum or other extrapulmonary speci-
men), or (2) a chest radiograph suggestive of tuberculosis
and at least one symptom of tuberculosis and receipt of
antitubercular drugs.
LP and Cerebrospinal Fluid Assay
All CrAg-positive participants were offered a diagnostic
LP after provision of verbal consent, regardless of neurolog-
ical symptoms suggestive of meningitis. Cerebrospinal ﬂuid
(CSF) CrAg LFA tests were performed twice, once by the
clinical staff at the patient’s bedside and a second time by
a technician at the laboratory. For participants with CrAg
detected in CSF, serial scheduled therapeutic LPs were
conducted on days 1, 3, 7, 10, and 14 of antifungal therapy.
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Antifungal Treatment
Participants with cryptococcal antigenemia and no men-
ingeal involvement received pre-emptive ﬂuconazole therapy
consisting of 14 days of 800-mg/d induction dose followed by
400 mg/d for 8 weeks and then 200-mg/d secondary pro-
phylaxis. Because of the lack of amphotericin or ﬂucytosine in
Tanzania, participants with CrAg detected in CSF were treated
with high-dose ﬂuconazole monotherapy as per national guide-
lines27 (ﬂuconazole 1200 mg/d for 14 days, followed by
ﬂuconazole 800 mg/d for 8 weeks and thereafter a secondary
prophylaxis of 200 mg/d). For those without evidence of
meningitis, ART was initiated after 2 weeks, and for those with
cryptococcal meningitis, ART was initiated at 6 weeks as per
WHO guidelines.5,28
Data Extraction and Statistical Analysis
All data were extracted from the KIULARCO cohort
databases.23,24 Baseline was deﬁned as the date of the ﬁrst
CrAg assessment. A window of 61 month from this date
was allowed to deﬁne baseline date for other
laboratory parameters.
A descriptive analysis of the cohort computed frequen-
cies and percentages with variables categorized based on
clinically meaningful ranges. Thereafter, we compared the
characteristics between CrAg-positive and CrAg-negative
participants. We assessed binary categorical variables
with x2 test and continuous variables with Kruskal–
Wallis nonparametric test.
Incidence rate of death/LFU was calculated by
dividing the number of death/LFU events by the person-
years at risk. Cox-proportional hazard models determined
the association between baseline characteristics and the time
to death/LFU by estimating the respective hazard ratio.
First, a univariate analysis estimated the unadjusted hazard
ratio and 95% conﬁdence intervals (95% CI) for the
baseline characteristics. A multivariate model was then
ﬁtted using the backward criteria by including in the
parsimonious model, using key parameters that did not
exceed 10% of the cases. Only variables whose univariate
association reached a statistical signiﬁcance (P , 0.1) were
selected. All models were adjusted for age and sex as
selected a priori confounders. The likelihood ratio test
compared the ﬁt of the different models. Participants with
missing data for a variable were excluded from models that
included that variable. Finally, Kaplan–Meier curves with
log-rank tests compared survival between CrAg-positive
participants with and without CSF involvement with CrAg-
negative participants.
All data were anonymized and analyzed using STATA
version 14.2 (Stata statistical software; Stata Corp, College
Station, TX).
FIGURE 1. Study profile of cohort.
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Ethical Considerations
Written informed consent to participate in KIULAR-
CO was sought from all participants at registration at the
CDCI, and all data were deidentiﬁed. The Ifakara Health
Institute institutional review board, the Health Research
Ethics Review Committee of the National Institute for
Medical Research of Tanzania, the Tanzanian Commission
of Science and Technology, and the Ethics Committee of the
University and State of Basel, Switzerland, provided ethical
approval for KIULARCO.
RESULTS
Between October 2013 and July 2015, 2023 individuals
were diagnosed with HIV infection at the HIV clinic,
outpatient clinics, and hospital medical wards. Of these, 713
(36%) patients did not consent to join the KIULARCO
cohort. Of the 1310 willing to join the cohort, 658 (50%) had
baseline CD4 .150 cells/mL, 31 (2.3%) were ,18 years-old,
and 61 (4.6%) had reported previous ART use. The remaining
560 ART-naive adult PLWHIV with CD4 #150 cells/mL
were included in the study (Fig. 1).
Table 1 summarizes the baseline characteristics of the
560 participants. Median CD4 count was 61 cells/mL [inter-
quartile range (IQR), 26–103], and 74% had ,100 cells/mL.
Overall, 78% had anemia with hemoglobin ,8 g/dL, and 9%
had tuberculosis. Overall, 26% of the new HIV diagnoses
occurred during hospitalization through the provider-initiated
HIV testing introduced in the medical wards.
Cryptococcal Antigen Prevalence
CrAg prevalence was 6.1% (34/560) among those with
CD4 #150 cells/mL and 7.5% (31/416) in those with CD4
#100 cells/mL. The concordance between the tests performed
at the bedside and at the laboratory was 100%. The CrAg
prevalence among inpatients was 12.6% (16/127) vs 4.2%
(18/433) among outpatients (P , 0.001). Median CD4 cell
counts were slightly lower among CrAg-positive compared
with CrAg-negative participants (52 cells/mL vs 62 cells/mL,
P = 0.08). Tuberculosis was more prevalent among CrAg-
positive individuals (22% vs 8%, P = 0.01) (Table 1).
Overall, 31% (10/34) of the CrAg-positive participants
had cryptococcal meningitis diagnosed by a positive CSF
CrAg. At diagnosis, 44% (15/34) of the participants did not
report any neurological symptoms, including one patient with
proven meningitis. Plasma CrAg titers were available for 24
CrAg-positive participants (71%). Overall, 25% (6/24) had
a plasma CrAg titer .1:160, including only 43% (3/7) of
those with CrAg detected in CSF and 18% (3/17) of
participants without meningitis (P = 0.20). Compared with
CrAg-positive outpatients, CrAg-positive inpatients had high-
er CrAg titers (62.5% vs 18.75% .1:160, P = 0.03).
Time Sequence From Cohort Enrollment
to Treatment
The median time from diagnosis of HIV infection to
enrollment into HIV care at the hospital was 1 day (IQR 0–3
days); to CD4 testing, 1 day (IQR 0–2); and to CrAg testing,
1 day (IQR 0–2), with all CrAg-positive participants receiv-
ing a diagnostic LP on the same day. A consented LP was
performed in 94% (32/34) of the CrAg-positive participants.
The two participants not receiving LPs had been diagnosed with
HIV at the outpatient clinic but did not return to the clinic.
Fluconazole tailored to meningitis status was started in 82% of
CrAg-positive patients overall (28/34), including 92% (22/24)
of those with nonmeningeal cryptococcosis and 60% (6/10) of
those with meningitis. The overall time to ﬂuconazole therapy
was a median of 3 days after CrAg testing (IQR 1–30 days),
including outpatients. ART was started in 68% (23/34) of CrAg-
positive participants. Reasons for not having started ART were
death (n = 9) and lost to follow-up (n = 2). Those CrAg-positive
participants without meningeal involvement started ART after
a median time of 22 days (IQR 16–41 days) vs 50 days (IQR
42–56 days) for those with CrAg detected in CSF (Fig. 2).
TABLE 1. Distribution of Baseline Characteristics of Study
Participants
Factor Total
CrAg-
Negative
CrAg-
Positive P*
Overall, n (%) 560 (100) 526 (100) 34 (100)
Women, n (%) 311 (56) 291 (55) 19 (59) 0.7
Age, years 38 (33–46) 38 (33–46) 41 (35–49) 0.3
Hemoglobin, g/dL 9.7 (8.3–11.2) 9.7 (8.3–11.2) 9.4 (8.2–0.9) 0.4
CD4, cells/mL,
median (IQR)
61 (26–103) 62 (26–105) 52 (28–105) 0.08
0–50, n (%) 229 (41) 213 (40) 16 (47) 0.06
51–100, n (%) 187 (33) 172 (33) 15 (44)
101–150, n (%) 144 (26) 141 (27) 3 (9)
Tuberculosis
treatment, n (%)
51 (9) 44 (8) 7 (22) 0.01
Neurological
symptoms,
n (%)
94 (17) 75 (14) 19 (56) ,0.001
Procedence, n (%) 0.001
Outpatient 420 (74) 399 (76) 17 (50)
Inpatient 144 (26) 127 (24) 17 (50)
Cryptococcal
meningitis,
n (%)
—
Positive CSF
CrAg
10 (2) — 10 (29)
Negative CSF
CrAg
22 (4) — 22 (65)
LP not
performed
528 (94) 526 (100) 2 (6)
ART initiated,
n (%)
461 (82) 438 (83) 23 (68) 0.021
6-month outcome,
n (%)
,0.001
Alive 335 (60) 320 (61) 15 (44)
Dead 56 (10) 43 (8) 13 (38)
LFU 119 (21) 114 (22) 5 (15)
Transferred 50 (9) 49 (9) 1 (3)
Numbers are n (column %) or median (IQR).
*P value from x2 test or Kruskal–Wallis rank test.
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate.
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Cryptococcosis Mortality and Risk Factors
Outcome analysis was restricted to 508 participants
after excluding 50 participants who were transferred to other
HIV clinics and the 2 plasma CrAg-positive participants with
unknown CSF status. These 508 participants contributed
a total of 3037 person-years at-risk follow-up time.
Of these 508 participants (all CD4 ,150 cells/mL), 335
(66%) completed 6 months of follow-up, and 173 participants
(34%) were dead or lost to follow-up. The overall 6-month
mortality rate in the cohort was 5.7 per 100 person-years
(95% CI: 4.9 to 6.6 per 100 person-years). Among CrAg-
positive participants, the mortality rate was 10.7 per 100
person-years (95% CI: 6.6 to 17.5 per 100 person-years)
overall, 7.3 per 100 person-years (95% CI: 3.7 to 14.6 per
100 person-years) for those without meningitis, and 20 per
100 person-years (95% CI: 1.02 to 40.6 per person-years)
with CSF CrAg-positivity (Table 2).
We assessed risk factors associated with survival. In the
univariate analysis, having CrAg detected in CSF was
associated with 4-fold higher 6-month mortality/LFU hazard
compared to participants with nonmeningeal cryptococcosis
(hazard ratio = 4.1; 95% CI: 2 to 8.4; P, 0.001). By contrast,
among CrAg-positive participants without CSF involvement,
there was a 1.5-fold increase hazard of death/LFU vs CrAg-
negative participants, which did not reach statistical signiﬁ-
cance (hazard ratio = 1.5; 95% CI: 0.8 to 3.1; P = 0.2, Fig. 3).
Other predictors of mortality/LFU in the univariate analysis
were anemia, low CD4, impaired renal function, and not
having received ART (Table 2). Mortality tended to be higher
among those participants with a high CrAg titer (above 1:160)
vs those with titers below this threshold (36% vs 20%), but
this difference did not reach statistical signiﬁcance. In the
univariate analysis, high titers were associated with a hazard
of death/LFU of 2.1 without reaching statistical signiﬁcance
(P = 0.236). Also, there was strong evidence suggesting that
time from HIV and CrAg testing to initiation of ﬂuconazole
therapy were associated with up to 19% reduction in the risk
of mortality (P = 0.004, data not shown). However, the
independent effect of these time factors was not further
explored in the multivariate analysis because of the small
number of observations.
After adjusting for age, sex, CD4 cell count, anemia,
and kidney function, factors signiﬁcantly associated with
6-month mortality included no ART initiation, CrAg detec-
tion in CSF, and low CD4 cell counts (Table 2). There was no
evidence of any effect of age, sex, anemia, or nonmeningeal
cryptococcosis on the risk of 6-month mortality (Table 2).
DISCUSSION
In this prospective cohort study of ART-naive PLHIV
with CD4 ,150 cells/mL in rural Tanzania, implementation of
provider-initiated HIV testing coupled with laboratory-reﬂex
CrAg testing of all persons entering into HIV care identiﬁed
a high prevalence of cryptococcosis. This prevalence was
1.7-fold higher than when retrospectively testing outpatients
only.16 CrAg-positive individuals treated with ﬂuconazole had
a similar 6-month survival as CrAg-negative individuals. After
adjusting for the effect of age, sex, renal function, and
hemoglobin level, CSF CrAg-positivity increased the risk of
mortality/LFU by nearly 3-fold while ART initiation reduced
the risk by 71%. We conﬁrmed our hypothesis that the
pragmatic approach of combining routine HIV testing among
both outpatients and hospitalized individuals with laboratory-
reﬂex CrAg testing, ﬂuconazole pre-emptive treatment, and
diagnostic LPs among CrAg-positive individuals would
improve cryptococcal disease detection in our facility. Our
historical survival was zero in CrAg-positive outpatients,
retrospectively identiﬁed, who did not receive ﬂuconazole.16
FIGURE 2. Timing from HIV diagnosis to ART initiation.
P values compare the median time between CrAg-positive
and CrAg-negative individuals. Overall, the median time
from entry into HIV care to CD4 testing, CrAg testing, and
referral for LP was 1 day in total with prioritization of ad-
dressing advanced HIV disease.
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We found a CrAg-positive prevalence of 7.5% among
those individuals with CD4 counts ,100 cells/mL and 2.1%
in those with CD4 counts between 100 and 150. Importantly,
we observed that survival among those with CD4 counts
.100 cells/mL did not differ compared to those with CD4
between 51 and 100 cells/mL (Table 2). This supports the
increase in the CrAg screening CD4 threshold as we had
previously suggested.16 CrAg prevalence was 3-fold higher
among hospitalized patients vs outpatients (12.6% vs 4.2%).
Indeed, half of the CrAg-positive individuals were diagnosed
TABLE 2. Univariate and Multivariate Analysis of Factors Associated With Death/LFU at 6 Months
Death or Lost to
Follow-up Person-Year Exposure Rate/100 Person–Years
Univariate Analysis
(N=508)
Multivariable Analysis
(N = 498)†
Hazard Ratio
(95% CI) P
Hazard Ratio
(95% CI) P
Age, years — — 1.01 (0.99 to 1.02) 0.32 1.01
(0.99 to 1.03)
0.19
Sex 0.88 0.81
Men 79 13.6 5.8 1.0 1.0
Women 94 16.7 5.6 1.02 (0.76 to 1.38) 1.04
(0.75 to 1.44)
CD4, cells/mL 0.04 0.02*
0–50 89 12.1 7.4 1.0 1.0
51–100 55 10.7 5.1 0.69 (0.49 to 0.96) 0.68
(0.48 to 0.96)
.100 29 7.6 3.8 0.66 (0.43 to 1.00) 0.66
(0.43 to 1.02)
Anemia 0.06 0.60
No 130 24.5 5.3 1.0 1.0
Yes 43 5.9 7.3 1.40 (0.99 to 1.99) 1.11
(0.76 to 1.61)
Non-CNS CrAg+ 0.25 N/A N/A
Negative 157 28.9 5.4 1.0
Positive 8 1.1 7.3 1.53 (0.75 to 3.12)
Meningitis in CrAg+ ,0.001 0.01
Negative 8 1.1 7.3 1.0 1.0
Positive 8 0.4 20 4.08 (2.00 to 8.37) 2.77
(1.31 to 5.83)
ART initiation ,0.001 ,0.001
No 55 3.9 14.2 1 1
Yes 118 26.5 4.5 0.29 (0.20 to 0.41) 0.32
(0.22 to 0.46)
Provider-initiated HIV test 0.13 N/A N/A
No 125 23.1 5.4 1
Yes 48 7.2 6.6 1.29 (0.92 to 1.81)
eGFR 0.03
$90 129 24.12 5.3 1 1 0.52*
30–89.9 32 4.9 6.5 1.38 (0.93 to 2.04) 1.19
(0.79 to 1.80)
,30.0 12 1.3 9.2 2.22 (1.22 to 4.05) 1.38
(0.72 to 2.65)
BMI, per kg/m2 0.22 N/A N/A
$25 11 2.5 4.5 1
18.5–24.9 88 17.2 5.1 1.37 (0.71 to 2.66)
,18.5 56 9.0 6.3 1.70 (0.86 to 3.36)
TB coinfection 0.48 N/A N/A
No 153 27.9 5.5 1
Yes 20 2.5 8.1 1.18 (0.74 to 1.90)
Variables included in the multivariable model were aged at CrAg test as a continuous variable, sex, CD4, anemia, cryptococcal meningitis, ART initiation, and eGFR. P value from
Wald test for binary variables and likelihood ratio test for categorical variables.
*P value for trend.
†Five hundred eight participants with known 6-months outcome included in the nivariate analysis. Ten participants with missing data for a variable excluded from the multivariate
models.
eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; PYR, person-years at risk.
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through provider-initiated HIV testing while hospitalized.
Likely, these hospitalized patients may have otherwise been
missed in absence of this strategy, and this suggests
reconsidering expanding consistently CrAg screening recom-
mendations to hospitalized PLHIV with low CD4 counts. As
most PLHIV who are hospitalized have low CD4 counts,
universal screening of hospitalized PLHIV should be consid-
ered in the absence of CD4 testing. Outpatient only CrAg
screening may likely underestimate the CrAg burden and
therefore miss opportunities to reduce AIDS mortality.
One-third of CrAg-positive individuals (10/34) were
diagnosed with meningitis by CSF CrAg positivity, including
one asymptomatic individual. Overall, only 1 of 23 (4%)
asymptomatic individuals was CSF CrAg-positive, and 9/10
participants with CSF CrAg-positivity were symptomatic with
CNS symptoms. Our experience shows a high LP acceptance
once detailed information was given on its risks and beneﬁts.
As expected, we also observed that cryptococcal meningitis
individuals had higher CrAg titers .1:160 as compared with
CrAg-positive individuals with no CSF involvement (43% vs
18%).10,17,29–31 However, because of the small sample size,
this difference did not reach statistical signiﬁcance (P = 0.20).
Nevertheless, these results may suggest that asymptomatic
patients with lower CrAg titers may not need diagnostic LPs to
rule out subclinical meningitis.
We implemented laboratory-reﬂex CrAg testing instead
of relying on the clinical evaluation, favoring a consistent rate
of testing and rapid communication of results vs provider-
initiated CrAg screening, as shown in previous studies.32–34
Through this implementation, we found no statistically
signiﬁcant difference in survival between CrAg-negative
individuals and those with nonmeningeal CrAg-positive
treated with ﬂuconazole, although the point estimate in the
univariate model pointed toward a 50% percent higher risk
mortality/LFU. Our ﬁndings are in-line with the existing
evidence on the survival beneﬁt of integrating early CrAg
screening and ﬂuconazole pre-emptive therapy when fungal
burden is low.10,16
By contrast, the observed 6-month mortality/LFU
among individuals with cryptococcal meningitis treated with
FIGURE 3. Kaplan–Meier survival estimates of death/lost to follow-up by CrAg status. A, (top left): Kaplan–Meier survival esti-
mates of death or LFU among CrAg-negative vs nonmeningeal CrAg-positive individuals. B, (top right): Kaplan–Meier survival
estimates of death or LFU among CrAg-negative vs cryptococcal meningitis individuals. C, (bottom left): Kaplan–Meier survival
estimates of death or LFU by CrAg status. D, (bottom right): Kaplan–Meier survival estimates of death or LFU among CrAg-
negative vs CrAg-positive by ART status.
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high-dose ﬂuconazole monotherapy was unacceptably high
(80%, 8/10). Despite the implementation of an optimized
meningitis clinical treatment protocol, including rapid CSF
testing after CrAg screening, high-dose ﬂuconazole, repeated
LPs, and intracranial pressure management, cryptococcal men-
ingitis mortality was equal to that observed in the historical
cohort.16 This ﬁgure compares with other studies from Tanzania
and sub-Saharan Africa where recommended antifungals such
as ﬂucytosine and amphotericin B are widely unavailable.4,14,35
Our ﬁndings therefore support the notion that approaches
centered exclusively on HIV treatment are inadequate in
reducing AIDS-related mortality and the undisputed need for
available ﬁrst-line antifungals for cryptococcal treatment.18,36
This study has several limitations. Selection bias is of
concern because our analysis excluded individuals who were
unable to provide ethical consent such as those who had an
altered mental state throughout admission. Nevertheless, this
may have underestimated the true prevalence of cryptococcosis
among admitted individuals. Also, ﬂuconazole was freely
available at the hospital through the President’s Emergency
Plan for AIDS Relief support until late 2014, but thereafter,
individuals were required to purchase ﬂuconazole. Fluconazole
adherence was not veriﬁed, and individuals requiring a longer
course may have defaulted treatment because of ﬁnancial
constraints. In addition, a composite outcome of death and loss
to follow-up was used because of suboptimal ascertainment of
mortality in the cohort. Given the contribution of loss to
follow-up to the 6-month outcome, the clinical endpoint of the
study might have substantial misclassiﬁcation. Indeed, in the
absence of postmortem studies, the ascertainment of the cause
of death was incomplete and based on clinical judgment.
Furthermore, the power of this study to detect the true estimate
is limited given the sample size. Finally, the lack of a survival
difference between those with nonmeningeal cryptococcosis,
and those CrAg-negative may suffer from a type-II statistical
error because of the lack of power, ﬁnding no difference when
one truly exists, and thus, these results have to be interpreted
with caution.
The main strengths of this study were the integration of
CrAg screening within routine clinical care and the pro-
spective nature of the clinical and laboratory data collected,
which allowed for correct estimation of incidence rates and
survival estimates. The electronic data collection, linking the
KIULARCO database with the information from the labora-
tory, outpatient, and medical wards, permitted estimation of
time from HIV testing to CrAg testing, LP, ﬂuconazole, and
ART initiation. To our knowledge, no previous studies have
estimated the effectiveness of such a model incorporated into
routine HIV care in rural sub-Saharan Africa.
In summary, these results conﬁrm that implementing
HIV testing in outpatients and in hospitalized individuals
coupled with CrAg laboratory-reﬂex testing and early initiation
of ﬂuconazole pre-emptive treatment increase detection of
cryptococcosis and may lead to a survival rate of nonmeningeal
cryptococcosis similar to that of CrAg-negative individuals
with comparable CD4 counts. Cryptococcal meningitis mor-
tality remains high in the absence of ﬁrst-line antifungals
despite timely diagnosis (median of 1 day from HIV testing),
treatment with high-dose ﬂuconazole, and proper management
of intracranial pressure as recommended by WHO. Recom-
mended ﬁrst-line antifungals are urgently needed to supple-
ment these efforts.
Our study suggests a feasible, effective, and scalable
model for CrAg screening and pre-emptive treatment strategy
to be integrated into routine care in rural sub-Saharan Africa.
We further support the recently adopted higher CD4 threshold
for CrAg screening and suggest to consistently extend these
WHO recommendations among hospitalized individuals as
part of the provider-initiated testing and counseling strategy.
These recommendations are pertinent to reduce the unaccept-
ably high mortality among people with advanced HIV disease
at a time where universal ART is being widely rolled out in
sub-Saharan Africa.
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